Table 1.
Characteristics of Transplant Survivors Studied
| Diagnosis | Non-Malignant | Lymphoid Malignancy | Myeloid Malignancy | CML |
|---|---|---|---|---|
| No. Patients | 53 | 69 | 68 | 24 |
| Age at Tx – yrs | 11.5 | 11.3 | 12.4 | 13.7 |
| Mean (range) | (1.7–17.9) | (3.4–17.4) | (1.9–17.9) | (3.9–17.8) |
| Study Age – Yrs Mean (range) | 32.1 | 27.3 | 27.1 | 24.9 |
| Gender M:F | 24:29 | 49:20 | 34:34 | 11:13 |
| Regimen S-TBI | 2 | 29 | 17 | 2 |
| Fx-TBI | 4 | 40 | 44 | 21 |
| BUCY | 4 | 0 | 7 | 1 |
| CY | 43 | 0 | 0 | 0 |
| Prior Treatment Less: More | 53:0 | 18:51 | 59:9 | 24:0 |
| Donor – Auto | 0 | 4 | 8 | 0 |
| Match | 53 | 53 | 48 | 16 |
| Mismatch | 0 | 12 | 12 | 8 |
| GVHD – Acute | 13 | 39 | 35 | 15 |
| Chronic | 10 | 16 | 22 | 12 |
| Severe Chronic | 1 | 3 | 4 | 1 |
Non-Malignant – includes aplastic anemia, immune deficiency, red cell aplasia Lymphoid Malignancy – includes acute lymphoblastic leukemia, Hodgkin Disease, Non-Hodgkin lymphoma, Myeloid Malignancy – includes acute myelogenous leukemia, myelodysplastic syndrome, juvenile myelomonocytic leukemia
CML – chronic myelogenous leukemia, TX – transplant, S-TBI is single fraction total body irradiation, FX TBI is fractionated total body irradiation, BUCY is busulfan plus cyclophosphamide, CY is cyclophosphamide only. Less treatment includes no cytotoxic therapy, first remission, untreated first relapse. More treatment includes second or greater remission, relapse, cranial irradiation. Auto is autologous, match is HLA matched related or unrelated donor, mismatch is HLA mismatched related or unrelated donor. GVHD = graft versus host disease